###begin article-title 0
###xml 57 60 57 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
Identification of critical residues in loop E in the 5-HT3ASR binding site
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 35 36 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The serotonin type 3 receptor (5-HT3R) is a member of a superfamily of ligand gated ion channels. All members of this family share a large degree of sequence homology and presumably significant structural similarity. A large number of studies have explored the structure-function relationships of members of this family, particularly the nicotinic and GABA receptors. This information can be utilized to gain additional insights into specific structural and functional features of other receptors in this family.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 38 41 38 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 454 455 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 469 470 465 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 577 578 573 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 686 689 682 685 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
Thirteen amino acids in the mouse 5-HT3ASR that correspond to the putative E binding loop of the nicotinic alpha7 receptor were chosen for mutagenesis. Due to the presence of a highly conserved glycine in this region, it has been suggested that this binding loop is comprised of a hairpin turn and may form a portion of the ligand-binding site in this ion channel family. Mutation of the conserved glycine (G147) to alanine eliminated binding of the 5-HT3R antagonist [3H]granisetron. Three tyrosine residues (Y140, Y142 and Y152) also significantly altered the binding of 5-HT3R ligands. Mutations in neighboring residues had little or no effect on binding of these ligands to the 5-HT3ASR.
###end p 4
###begin title 5
Conclusion
###end title 5
###begin p 6
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 101 102 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 157 158 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
Our data supports a role for the putative E-loop region of the 5-HT3R in the binding of 5-HT, mCPBG, d-tc and lerisetron. 5-HT and mCPBG interact with Y142, d-tc with Y140 and lerisetron with both Y142 and Y152. Our data also provides support for the hypothesis that this region of the receptor is present in a loop structure.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 120 121 120 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 543 545 543 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A</sub>
###xml 580 581 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 582 583 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 584 585 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 650 651 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 652 653 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 654 655 650 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 744 745 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 746 747 742 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
Sequence homology between the serotonin type 3 receptor (5-HT3R), the nicotinic acetylcholine receptor (nAChR), the GABAA receptor and the glycine receptor suggests a large amount of structural similarity within this superfamily of ligand gated ion channels[1-3]. This presumed structural homology can be used to guide site directed mutagenesis studies of particular receptor subtypes. On a gross level, all members of this superfamily assemble as pentameric receptors [4]. In some cases, receptors can be assembled from a single subunit (5-HT3AR and nicotinic alpha7 receptors) [1,5-8]. In other cases, at least two different subunits are required [2,4,9]. The ligand binding site is thought to be formed at the junction between two subunits [2,4].
###end p 8
###begin p 9
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 462 463 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 464 466 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 869 870 865 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
Based on data obtained from affinity labeling and site directed mutagenesis studies, several regions of the nicotinic acetylcholine receptor have been implicated in ligand binding [10]. Six essential loops appear to contribute to the binding site with the position of each loop differing slightly depending on whether the receptor is heteromeric or homomeric[4]. For homomeric receptors such as the alpha7 nAChR, the loops are identified as A, B, C, D, E and F [4,11]. The amino acids that interact with ligands presumably extend into the binding site from these loops. Subunits are composed of 2 faces (+ and -) with the + face of one subunit forming one side of the binding site and the - face of another subunit forming the complimentary side. Some binding loops (A, B and C) are present on the - face while the remaining loops (D and E) are present on the + face. [4]. The individual amino acids that form binding interactions with the functional groups present on a ligand are likely to differ for each receptor subtype, reflecting the specificity of a particular binding site, however, the overall structure of the binding domain may be similar even for binding sites with different ligand specificities. Identification of ligand specificity requires identification of both the location or structure of individual binding site loops and the amino acids present in a particular receptor subtype.
###end p 9
###begin p 10
###xml 119 120 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 256 258 256 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A</sub>
###xml 308 309 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 799 800 799 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1196 1197 1196 1197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1360 1361 1360 1361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1379 1380 1379 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
The purpose of this study is to extend the information available from other members of this receptor family to the 5-HT3R. Sequence homology and a presumed structural similarity to other ligand gated ion channels suggests that the E loop region of the 5-HT3AR forms part of the ligand binding domain for 5-HT3R ligands. This region extends from Y140 to K153 and is shown in Table 1. The homologous sequences of other representative members of this family are also shown. In the center of this region is a critical glycine residue that is thought to play a role in establishing a hairpin loop [12]. Recent x-ray crystallographic data obtained from an ACh binding protein (AChBP) shows a loop structure in this region resulting from a 3 residue turn containing a glycine homologous to G147 of the 5-HT3R. On either side of this putative turn region are residues that have been identified as important to receptor binding [12-18]. The formation of this loop structure brings amino acids on either side of glycine into close proximity and may form a binding pocket that will accommodate one or more functional groups. In order to identify the interaction of amino acids in this binding loop with 5-HT3R ligands, we have constructed alanine mutations of residues throughout this region and evaluated the alteration in binding affinity of 5 different classes of 5-HT3R ligands (Figure 1). Our data identifies 3 tyrosine residues that appear to interact selectively with each structural class and supports the existence of a loop structure in this region of the receptor.
###end p 10
###begin p 11
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
5-HT3R ligands.
###end p 11
###begin p 12
Sequence Comparison of Putative Binding Loop Region.
###end p 12
###begin p 13
###xml 221 222 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
Primary amino acid sequence of representative members of the LGIC superfamily showing amino acid residues on either side of the conserved glycine residue. The amino acids shown span the region from Y140 - P154 of the 5-HT3R. The conserved glycine is shown in bold. Amino acids identified in the binding site of other LGIC subunits and the tyrosines identified in this study are shown in red, bold italics [11-17].
###end p 13
###begin title 14
Results
###end title 14
###begin p 15
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 117 118 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 149 152 149 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 251 252 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 336 338 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 339 341 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 345 348 343 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 625 626 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 627 629 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 630 632 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 773 774 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 898 899 896 897 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 962 964 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1050 1051 1048 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 139 144 <span type="species:ncbi:10090">mouse</span>
All mutant receptors were tested for their ability to bind the 5-HT3R antagonist [3H]granisetron. Table 2 shows the Kd values for wildtype mouse 5-HT3ASRs and the 13 alanine mutations we evaluated. [3H]granisetron is a potent antagonist of the wt 5-HT3R (Kd = 0.98 +/- 0.12 nM). This value agrees with published data for this compound [19,20]. Bmax values range from the 5.5 pmoles/mg protein observed for E148A to 0.30 pmoles/mg protein for the K153A mutation, indicating some variability in expression of the different receptors. In general, however, receptor expression was similar to that reported by other laboratories [1,20-22]. No detectable binding was observed for G147A and V149A mutant receptors. For all other mutants, decreases in binding affinity (increased Kd) were observed although the magnitude of the change was less than 10 fold in all cases. A bar graph showing the change in Kd value resulting from each alanine mutation is shown in Figure 2A. The largest decreases in binding affinity were observed for Y142A (4.6 fold, Figure 3), E148A (5.3 fold) and Q150A - K153A (6 - 8 fold).
###end p 15
###begin p 16
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Changes in K<sub>i</sub> or K<sub>d</sub> (for binding of [<sup>3</sup>H]granisetron) as a result of alanine mutations.</bold>
###xml 126 127 126 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 132 133 132 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 243 244 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 249 250 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 346 347 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 352 353 352 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 355 357 355 357 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A.</bold>
###xml 506 508 506 508 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B.</bold>
###xml 521 522 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 673 674 673 674 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 713 718 713 718 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5-HT:</bold>
###xml 789 790 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 789 795 783 789 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>m</italic>CPBG:</bold>
###xml 865 866 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 865 870 853 858 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d</italic>-tc:</bold>
###xml 936 947 918 929 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lerisetron:</bold>
Changes in Ki or Kd (for binding of [3H]granisetron) as a result of alanine mutations. The values shown are the ratio of the Kd or Ki for wildtype and mutant receptors. The length of each bar illustrates the magnitude of change in either the Kd or Ki relative to wildtype while the direction indicates an increase (up) or decrease (down) in the Kd or Ki. A. Most alanine mutations produced little change in Kd. No binding was detected for the G147A and V149A receptors therefore no Kd could be determined. B. Changes in Ki were small for most receptors although large changes were observed for select ligands at Y140A, Y142A and Y152A receptors. The relative increases in Ki for these amino acids are as follows: 5-HT: Y140A 1.3 +/- 0.30 fold, Y142A 110 +/- 25 fold, Y152A 24 +/- 5.6 fold mCPBG: Y140A 7.3 +/- 1.7 fold, Y142A 160 +/- 36 fold, Y152A 24 +/- 5.6 fold d-tc: Y140A 50 +/- 12 fold, Y142A 6.5 +/- 1.5, Y152A 10.0 +/- 2.3 fold lerisetron: Y140A 4.6 +/- 1.1 fold, Y142A 160 +/- 37 fold, Y152A 190 +/- 43 fold
###end p 16
###begin p 17
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Saturation binding isotherms for binding of [<sup>3</sup>H]granisetron to wildtype, Y140A, Y142A and Y152A receptors.</bold>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 340 341 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 464 465 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 516 517 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 527 530 527 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Saturation binding isotherms for binding of [3H]granisetron to wildtype, Y140A, Y142A and Y152A receptors. The data shown represent the specific binding of [3H]granisetron as determined from at least four identical experiments. Specific binding was determined as the fraction of total binding not inhibited by a saturating concentration of mCPBG or MDL-72222. Data were combined and fitted using non-linear curve fitting. Only small shifts in binding affinity to [3H]granisetron were observed on all three mutants. Kd values, Bmax and Hill coefficients are shown in Table 2.
###end p 17
###begin p 18
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 51 54 51 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
[3H]Granisetron binding to wildtype and mutant 5-HT3ASRs.
###end p 18
###begin p 19
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 9 12 9 12 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 244 245 242 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 305 306 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 466 467 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
The Kd, Bmax and Hill coefficient (n) were determined using non-linear curve fitting of binding data as described in the methods section. Each value represents the combined data from at least four experiments and is represented as +/- SE. The Kd values were used to calculate the ratios plotted in Figure 2, indicating the change in binding affinity as a result of each individual mutation. A plot of the data obtained from Y140A, Y142A and Y152A is shown in Figure 3.
###end p 19
###begin p 20
###xml 126 127 126 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 302 303 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 415 416 415 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 524 525 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 552 553 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 640 641 640 641 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 730 731 730 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 795 796 795 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 837 838 837 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
Inhibition binding assays were also conducted. Four test compounds with structures representative of the major classes of 5-HT3R ligands were chosen: serotonin (5-HT, the endogenous agonist), m-chlorophenylbiguanide (mCPBG, agonist), d-tubocurarine (d-tc, antagonist) and lerisetron (antagonist). The Ki values for inhibition of [3H]granisetron binding by all four compounds are shown in Table 3. Little change in Ki value was observed for the majority of mutations. The values highlighted in bold in Table 3 represent the Ki values for inhibition of [3H]granisetron binding on mutant receptors that increased over 10 fold compared to the Ki obtained for wildtype receptors. The bar chart in Figure 2B illustrates the changes in Ki resulting from each mutation on the test compounds. Ratios of Ki are shown as positive for increases in Ki on mutant receptors versus wildtype and negative for decreases. A positive change thus corresponds to a decrease in binding affinity for the compound as a result of the mutation. Large decreases in binding affinity were observed for select compounds only on the Y140A, Y142A and Y152A mutations.
###end p 20
###begin p 21
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 80 83 80 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
Ki values for Inhibition of [3 H]granisetron binding to wildtype and mutant 5-HT3ASRs.
###end p 21
###begin p 22
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 118 119 118 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 154 156 154 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 196 197 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 271 272 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 369 370 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 420 421 418 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
IC50 values were determined from competition binding data using [3H]granisetron as described in the methods section. Ki values were calculated from the IC50 using the Cheng-Prusoff equation, the Kd value, and the concentration of [3H]granisetron (typically equal to the Kd). Each value represents the combined data from at least four experiments and is represented as Ki +/- SE. Values in bold type indicate changes in Ki greater than or equal to 10 fold on mutant vs. wt receptors.
###end p 22
###begin p 23
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 246 247 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 315 316 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 366 367 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 511 512 511 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
A more detailed analysis of the competition binding data obtained for the Y140A, Y142A and Y152A mutations is shown in Figure 4. For 5-HT, the Y142A mutation produced a 110 fold increase in Ki and Y152A produced a 24 fold increase. No change in Ki was observed for the Y140A mutation (Figure 4A). The 5-HT3R agonistmCPBG showed a similar profile for the changes in Ki values resulting from mutations of the three tyrosines (Figure 4B). As was observed for 5-HT, the Y142A mutation produced a large increase in Ki (160 fold) while the Y14 0A and Y152A mutations produced only 7 and 24 fold changes respectively.
###end p 23
###begin p 24
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of [<sup>3</sup>H]granisetron binding by 5-HT<sub>3</sub>R ligands.</bold>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 307 309 307 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 471 472 471 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 568 569 568 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 602 603 602 603 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 610 611 610 611 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 613 614 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 619 620 619 620 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 626 627 626 627 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
Inhibition of [3H]granisetron binding by 5-HT3R ligands. The data represent the combined results of at least four experiments. Assays were conducted as described in Materials and Methods. Fractional response is the fraction of [3H]granisetron binding obtained in the presence and absence of inhibitor. An IC50 value was determined from the data using non-linear curve fitting as described in the methods and the Ki value calculated using the Cheng-Prusoff equation, the Kd as determined in Figure 3 and the concentration of ligand used to obtain the inhibition data. Kd values are reported in Table 3. A. 5-HT B. mCPBG C. dtC D. Lerisetron
###end p 24
###begin p 25
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 17 18 17 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 228 229 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
The Ki value for d-tc inhibition of [3H]granisetron binding was altered only slightly by the Y142A or Y152A mutations (6.5 fold and 10 fold changes respectively). The Y140A mutation, however, produced a 50 fold increase in the Ki compared to wildtype receptors (Figure 4C).
###end p 25
###begin p 26
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 278 279 278 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 371 372 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 386 387 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
The Ki value for lerisetron inhibition of [3H]granisetron binding was increased 160 fold by the Y142A mutation and 190 fold by the Y152A mutation. Only a 4.6 fold change in Ki resulted from the Y140A mutation. Lerisetron was the only compound for which a large increase in the Ki was observed on the Y152A mutation (Figure 4D). This mutation produced smaller changes in Ki for 5-HT and mCPBG (24 fold for both) and only a 10 fold change for d-tc.
###end p 26
###begin p 27
###xml 461 463 461 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 516 517 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 575 577 574 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 653 654 652 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
In whole cell patch clamp studies, 5-HT perfusion of cells transfected with Y140A and Y142A cDNA produced no responses at 5-HT concentrations of up to 1 mM although specific binding to these receptors was identified in receptor binding studies. Unlike Y140A and Y142A, Y152A receptors responded to application of 5-HT. Due to the low potency of 5-HT on these receptors, only a portion of the concentration response curve could be determined (up to 1 mM). The EC50 value was estimated as greater than 370 muM (Figure 5). This value shows a greater than 140 fold increase in EC50 compared to wildtype receptors; a larger change than was observed for the Ki (24 fold). The most dramatic change observed for whole cell currents was an alteration in the kinetics of the response elicited by application of 5-HT. Y152A mutant receptors displayed much slower rise times compared to wildtype receptors at all concentrations tested. Peak wt responses were typically obtained in less than 80 ms while Y152A responses required several seconds to plateau. Desensitization kinetics were also altered. While wt receptors desensitized rapidly, mutant receptors showed no desensitization during the 8 s perfusion time.
###end p 27
###begin p 28
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Whole cell patch clamp recording from tsA 201 cells transfected with wildtype and Y152A cDNA.</bold>
###xml 198 201 198 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 479 480 479 480 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 495 498 495 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 723 724 718 719 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1081 1082 1073 1074 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1143 1146 1135 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 1335 1337 1326 1328 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 1376 1377 1362 1363 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1441 1444 1427 1430 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 1666 1668 1652 1654 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 1735 1738 1721 1724 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1746 1748 1732 1734 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 1754 1755 1740 1741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">n</sup>
###xml 1819 1821 1805 1807 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 1933 1936 1919 1922 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 2136 2138 2122 2124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
Whole cell patch clamp recording from tsA 201 cells transfected with wildtype and Y152A cDNA. Data were obtained using whole cell patch clamp on tsA201 cells transfected with wt or Y152A mutant 5-HT3ASR cDNA. Cells were clamped at a holding potential of -60 mV and 5-HT applied with a rapid perfusion system. The application time for 5-HT is indicated by the bar above the curves. The responses indicated in A and B are representative examples of at least 4 sets of experiments. A. Wildtype 5-HT3ASR. 5-HT was applied as indicated for a 4 s duration. The concentrations of 5-HT used and the response amplitudes are: a. 0.3 muM (0.03 nA) b. 1.0 muM (0.96 nA) c. 3.0 muM (2.5 nA) d. 30.0 muM (4.4 nA), e. 100.0 muM (3.9 nA). B. Y152A mutant receptors. 5-HT was applied as indicated for an 8 s duration. The curves in B were offset vertically for clarity. The dashed line in each curve indicates the baseline level for that response. The concentrations of 5-HT used and the response amplitudes are: f. 3.0 muM (0.10 nA) g. 100 muM (0.14 nA) h. 300.0 muM (0.57 nA) i. 1.0 mM (1.0 nA). C. Concentration response curve for 5-HT activation of wt 5-HT3ASRs. Each data point represents the combined results of 4 experiments. Responses were normalized to the response obtained at 30 muM and the curves fit as described in the methods section. EC50 = 2.7 +/- 0.25 muM, n = 1.6 +/- 0.22. D. Concentration response curve for 5-HT activation of Y152A 5-HT3ASRs. Each data point represents the combined results of 4 experiments. The response did not plateau in the range of concentrations used and hence responses were normalized to the maximum concentration of 5-HT (1 mM). The EC50 was estimated by fitting the data to the following equation: I = Imax/(1 +(EC50/ [C])n), where is the normalized current at 5-HT concentration [C], EC50 is the concentration of 5-HT needed to obtain half maximal activation and n is the apparent Hill coefficient. Imax in this case represents the estimated maximum current relative to the response obtained at 1 mM. To obtain the curve shown in the figure, the Hill coefficient was fixed at the wt value of 1.6. The EC50 value obtained from this fit is 370 +/- 27 muM.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 114 115 114 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 257 258 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 513 514 513 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 620 623 620 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 706 707 706 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 610 615 <span type="species:ncbi:10090">mouse</span>
The putative E-loop region of the LGIC family of receptors is homologous to residues Y140 through K153 in the 5-HT3R [4,12-18]. Structure-function studies of this region have been conducted in several other members of this family of receptors including GABAA and nAChR subtypes. In each case, residues have been identified that alter either the binding of selective ligands or receptor function [4,11-18]. In order to determine if this loop also contains residues critical to the structure or function of the 5-HT3R, we have constructed alanine mutations of amino acids throughout the homologous region of the mouse 5-HT3ASR and investigated the affects on binding of 5 different structural classes of 5-HT3R ligands. We have identified three tyrosine residues that appear to play a role in binding of selective ligands to this receptor. In addition, our data support the existence of a loop structure in this region as has been hypothesized for the nAChR and identified in a homologous AChBP [12,23,24].
###end p 30
###begin p 31
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 550 551 550 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 556 557 556 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 596 597 596 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 663 664 663 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 669 670 669 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 742 743 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
Representative members of 5 major structural classes of 5-HT3R ligands were tested on all mutants (Figure 1). These ligands include the antagonists [3H]granisetron, d-tc and lerisetron, and the agonists 5-HT and mCPBG. Most of the mutations tested produced only minor changes in binding affinity for these ligands. Large changes in binding are only apparent on Y140A, Y142A and Y152A receptors for select ligands. The resulting effects of individual mutations are specific to particular structural classes of ligands. The Y140A mutation altered the Ki for d-tc inhibition, but did not alter the Ki obtained for any other compound tested, while Y142A altered the Ki for mCPBG, 5-HT and lerisetron but had little if any effect on inhibition by d-tc. These data indicate the highly specific nature of the effects introduced by the alanine mutations and appear to reflect specific changes in ligand/receptor interaction.
###end p 31
###begin p 32
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 262 263 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 325 326 325 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 373 374 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 380 381 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
Binding of [3H]granisetron is altered only slightly by the alanine mutations introduced in this study (<10 fold). This result indicates the lack of involvement of amino acids in this binding loop in the binding of [3H]granisetron. It is apparent, however, that [3H]granisetron does occupy the same binding cleft as other 5-HT3R ligands as evidenced by the ability of 5-HT, mCPBG, d-tc and lerisetron to displace it from the binding site. The lack of any large change in binding of granisetron supports our contention that there is little global structural perturbation of the binding site resulting from the introduction of each individual alanine mutation.
###end p 32
###begin p 33
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 770 771 770 771 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1254 1256 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1265 1271 1265 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et. al</italic>
###xml 1374 1375 1373 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 1381 1383 1380 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1484 1485 1483 1484 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The Ki for inhibition of [3H]granisetron binding by 5-HT was increased 110 fold by the Y142A mutation. A similar increase was also observed for mCPBG (160 fold). In contrast, the Y140A and Y152A mutations produced relatively small changes in the Ki. Since both compounds are 5-HT3R agonists, they are likely to share the same binding interactions. One of these interactions appears to be with Y142. Other studies have also identified binding site interactions for agonists. R91, E106, F107, W183 and several residues adjacent to the M1 region have all been demonstrated to alter the action of 5-HT and/or mCPBG [20,21,25,26]. Within the crystal structure of the AChBP, homologous residues are located in the apparent binding site [24]. The effects of agonist on the 5-HT3R are mediated by their interaction with these binding site residues, resulting in stable receptor conformations, including the channel open state. Identification of interacting amino acids and their location in the tertiary structure of the receptor may provide clues to the mechanism of channel opening. For example, amino acids homologous to Y142 and W183 (R104 and W143 respectively) are in close proximity in the AChBP, although on complementary faces of the receptor subunits [24]. Spier et. al. have suggested that W183 may be involved in a cation-pi interaction with the amino group of 5-HT and mCPBG [26]. If W183 and Y142 are located near each other but on opposite faces of the binding site in the 5-HT3R, then they could potentially act in concert to help stabilize a conformation of the receptor leading to channel opening.
###end p 33
###begin p 34
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 490 491 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 532 533 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 542 543 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 607 608 607 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 714 715 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 795 796 795 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 880 881 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 899 900 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 922 925 922 925 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 929 931 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1083 1084 1083 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1171 1173 1171 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1180 1181 1180 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1362 1363 1362 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1543 1544 1543 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
d-Tubocurarine inhibition was uniquely altered by the Y140A mutation. An increase in Ki of 50 fold was observed for d-tc on this mutant. Little if any change resulted for any other mutation. Thus, while d-tc may form an interaction with the receptor at this binding loop, it appears to interact with Y140 rather than Y142 or Y152. This difference in binding site interactions of the antagonist d-tc and the agonists 5-HT and mCPBG could be the result of a slightly different positioning of d-tc in the binding site. The antagonists d-tc and [3H]granisetron also interact differently with this region since [3H]granisetron binding was not altered by mutations at any of the amino acids tested. While the binding of d-tc appears to involve some interaction with this binding loop, the binding of [3H]granisetron does not. Previous studies have indicated a point of overlap between [3H]granisetron and d-tc at W89 of the 5-HT3ASR. [20]. These studies indicate that the binding regions for these antagonists are partially overlapping at W89 but not at Y140. In addition to Y140 and W89, d-tc has also been observed to interact with D206 and several other residues in loop C [27]. The d-tc binding site appears to involve interaction with at least three different binding loops (A, E and C) although additional interacting amino acids may be found. Data obtained for d-tc is particularly valuable due to the rigid nature of this molecule. Determination of interacting functional groups and their relationship to individual amino acids could enable d-tc to be used as a molecular ruler to determine relative positions of these amino acids.
###end p 34
###begin p 35
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 119 120 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 161 168 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et. al.</italic>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 198 199 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 308 309 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 372 373 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 644 645 644 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 738 739 738 739 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 781 782 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 791 792 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Lerisetron inhibition of [3H]granisetron binding to mutant receptors was also investigated. Lerisetron is a potent 5-HT3R antagonist first synthesized by Orales et. al.[28]. As was observed for 5-HT3R agonists, lerisetron binding was altered by the Y142A mutation. This mutation produced an increase in the Ki of 160 fold compared to wildtype receptors. This increase in Ki indicates an important interaction of lerisetron with Y142 and a similarity between the binding location of lerisetron, 5-HT and mCPBG. Lerisetron is the only antagonist tested that shares a binding site interaction in this region with agonists. In contrast to 5-HT and mCPBG, however, lerisetron also interacts with Y152 as indicated by the 190 fold increase in Ki on Y152A mutant receptors. Since neither d-tc nor [3H]granisetron interacts with Y142 or Y152, there appears to be a difference between the interactions formed by these antagonists compared to lerisetron. The binding sites of the three antagonists tested differ with respect to this binding loop. Since the role of a competitive antagonist is simply to block the binding of agonists and prevent channel opening, the specific amino acids that interact with the ligand can vary for different antagonists. This is less likely to be the case with agonists since they must produce a conformational change in the protein to exert their effects.
###end p 35
###begin p 36
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 144 151 144 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et. al.</italic>
###xml 348 350 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 757 759 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1116 1118 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1119 1121 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1238 1240 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1336 1337 1307 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1413 1414 1384 1385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1506 1507 1477 1478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1682 1685 1641 1644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
Only two mutant receptors failed to bind [3H]granisetron; G147A and V149A. G147 is the conserved glycine in this putative binding loop. Chirara et. al. have suggested that the highly conserved nature of the glycine in this region may indicate the existence of a loop structure consisting of either gamma or a loose three residue-turn in the nAChR [12]. Either of these turns would bring the two putative beta-strands together such that gammaL109, gammaY111 and gammaS115 and gammaY117 are all on the same side of an antiparallel beta-sheet. These residues have been identified by affinity labeling, site-directed mutagenesis or cysteine substitution to lie on the same surface. A classic 2-residue beta-turn would place these residues on opposite surfaces [12]. Substitution of the conserved glycine by alanine may disrupt the structure of this region and prevent assembly or expression of the receptor. The recent determination of the crystal structure of an AChBP supports this hypothesis. The AChBP displays a large amount of homology to the amino terminal of LGIC receptors and thus may be similar in structure [20,24]. The crystal structure of this protein reveals a loose 3 residue turn incorporating the conserved glycine residue [24]. Homologous residues in other LGIC subunits have also been identified and are shown in Figure 1. The residues identified in this study as altering binding affinity of 5-HT3R ligands would also be present on the same surface if this structure is present in the 5-HT3R. While Y140 lies somewhat outside the region identified by Chiara in the nAChR (homologous to gammaN107), gammaL109 and gammaL119 are homologous to Y142 and Y152 of the 5-HT3ASR. The ability of lerisetron to interact with both Y142 and Y152 also supports the hypothesis that these two amino acids are present in a loop structure since the eight intervening residues would position Y142 and Y152 too far apart to permit them both to interact with a single ligand even if they were interacting with functional groups on opposite ends of the molecule. A loop structure would bring them into closer proximity and permit interaction with the small molecule lerisetron.
###end p 36
###begin p 37
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 345 346 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
All three tyrosine mutations were investigated using a whole cell patch clamp assay to determine if functional changes could be observed. Whole cell responses could not be obtained for Y140A or Y142A, although specific binding of [3H]granisetron was observed. These data suggest that, while the receptors do assemble and are capable of binding [3H]granisetron, they are either not transported to the cell surface or are non-responsive to 5-HT at concentrations of 1 mM or less.
###end p 37
###begin p 38
###xml 468 470 468 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 644 647 644 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 866 867 866 867 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 983 984 983 984 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 1109 1111 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1316 1317 1300 1301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1514 1516 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1586 1587 1570 1571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1140 1145 <span type="species:ncbi:10090">mouse</span>
###xml 1150 1153 <span type="species:ncbi:10116">rat</span>
Y152A does produce functional channels however they display distinctly altered response kinetics when compared to wildtype receptors. Y152A responses do not show the rapid rise times observed in wt receptors. The extremely slow rise times observed for Y152A receptors may indicate a change in rate constants preceding channel opening. These changes in the rate constants for either agonist binding or channel opening also produce a 140 fold decrease in the observed EC50 for 5-HT activation. The slow rise is followed by a non-desensitizing phase of the response that is dramatically different from the fast desensitization observed for wt 5-HT3ASRs. Lack of desensitization could result from either a stabilization of the open state of the channel or a destabilization of the desensitized state. Mutations of homologous or nearby residues in both the nAChR and GABAA receptors have also been demonstrated to alter the agonist response. Mutation of the homologous residue in the GABAA receptor gamma-subunit (T142) to serine altered the efficacy of the agonist Flumazenil, converting it to a partial agonist [29]. In the nAChR, mutation of mouse and rat epsilonP121 to leucine altered both the binding of acetylcholine and the stability of the open state of the channel. epsilonP121 is homologous to P154 in the 5-HT3R and is only two residues away from Y152. The authors of this study concluded that this portion of the acetylcholine binding site was closely linked to the channel opening region of the receptor [30]. It is reasonable to conclude that the homologous region in the 5-HT3R may perform a similar function. The link between an agonist binding domain and a conformational change leading to channel opening is not unexpected since the two must obviously be linked. If binding to this region of the receptor is shown to be a critical step between the binding of agonists and the opening of the channel, further investigation of the amino acids in this loop may provide valuable clues to molecular basis of this process.
###end p 38
###begin title 39
Conclusions
###end title 39
###begin p 40
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 325 326 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 440 441 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1106 1107 1106 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1135 1136 1135 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1149 1150 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
Our data indicate an important role for this putative binding site loop in the interaction of the 5-HT3R with different ligands and illustrate the difference in binding of different structural classes of ligands. Each structural class shows different patterns of interaction with amino acids in this region of the receptor. [3H]granisetron does not appear to interact with any of the amino acids tested while d-tc interacts with only Y140, mCPBG and 5-HT with Y142 and lerisetron with both Y142 and Y152. Similar selective effects have been observed on other residues including W183, W89, F107 and E106 among others[20,21,25,26]. Our data in conjunction with those of other laboratories indicates the differences in orientation of different ligands within the same binding cleft. These differences in orientation result in different amino acid/functional group interactions. As the structural detail of these interactions emerges, these differences could potentially be exploited to produce more potent and specific ligands. For example construction of a "hybrid" ligand that combines the interactions of [3H]granisetron with those of d-tc, 5-HT or mCPBG could produce an antagonist with increased affinity due to the additional binding energy of these interactions and a greater specificity since it would utilize more structural features of the binding site.
###end p 40
###begin p 41
###xml 277 284 277 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et. al.</italic>
###xml 331 332 331 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 715 717 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 718 720 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 594 599 <span type="species:ncbi:10090">mouse</span>
The requirement of a glycine at position 147 and the ability of lerisetron to interact with both Y142 and Y152 also support the hypothesis that the secondary structure in this region of the receptor is formed by a loop structure. If the loose 3 residue turn proposed by Chiara et. al. and shown for the AChBP is present in the 5-HT3R, then Y140, Y142 and Y152 would be present on the same side of the sheet and all three would be capable of extending into the binding site. A similar observation has been made for the nAChR where gammaS111, gammaY117, gammaL119, deltaR113 and deltaT119 of the mouse nAChR receptor and gammaL109 and gammaY111 of the torpedo nAChR are all thought to be present in the binding site [12-18].
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
Materials
###end title 43
###begin p 44
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
[3H]granisetron was purchased from New England Nuclear, 5-HT from Spectrum, and mCPBG and d-tc from Research Biochemical International. Lerisetron was provided by Dr. Karen Kirschbaum at The University of Louisiana at Monroe, Monroe, LA. All other reagents were obtained from commercial sources.
###end p 44
###begin title 45
Site directed mutagenesis
###end title 45
###begin p 46
###xml 14 17 14 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
Wild type 5-HT3AS mouse receptor cDNA was obtained from Dr. Michael White [20]. Mutant receptors were constructed using either the Quick Change Mutagenesis kit (Stratagene) or the Altered Sites Mutagenesis kit (Promega). All mutations were confirmed by commercial DNA sequencing.
###end p 46
###begin title 47
Cell culture and transfection
###end title 47
###begin p 48
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 211 212 211 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 251 254 250 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3AS</sub>
###xml 241 246 <span type="species:ncbi:10090">mouse</span>
tsA201 cells, a derivative of HEK293 cells, were seeded at a density of 5 x 106 cells/100 mm dish. Cells were grown in DMEM medium containing 10% FBS, 100 units/ml penicillin/streptomycin for nine hours in 5% CO2 and transfected with 10 mug mouse 5-HT3ASR cDNA per 100 mm dish using the calcium phosphate technique (New Life Technologies, NY). Media was changed 12-14 hrs after transfection. The cells were allowed to grow for another 24 hours and then harvested.
###end p 48
###begin p 49
###xml 90 91 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
For whole cell patch clamp experiments, tsA201 cells were seeded to a density of 0.25 x 106 cells/60 mm dish. Cells were grown in DMEM culture medium containing 10% FBS and 100 units/ml penicillin/streptomycin for 12 hours prior to transfection. Transfections were performed using Superfect Transfection Reagent (Qiagen, CA). Ten mug of cDNA were mixed with DMEM medium containing no serum or antibiotics in a volume of 150 mul. Twenty mul of Superfect reagent were then added and the mixture incubated at room temperature for 15 min. The reaction was terminated by adding 1 ml of DMEM medium containing 10% FBS and 100 units/ml penicillin/streptomycin and the entire mixture added to cells in the 60 mm dish. Cells were exposed to Superfect Reagent for 3 hours. At that time, the reagent was replaced with DMEM medium containing 10% FBS and 100 units/ml penicillin/streptomycin and incubated for an additional 24 hours prior to use.
###end p 49
###begin title 50
Binding assays
###end title 50
###begin p 51
###xml 631 634 619 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 640 641 628 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 816 819 804 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 882 885 870 873 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 945 948 931 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
Transfected cells were scraped from the dishes, washed twice with Dulbecco's PBS (New Life Technologies, NY), then resuspended in 1.0 ml ice cold PBS/100 mm dish. Cells were either used fresh or frozen at this step until needed. Immediately prior to use, cells were homogenized on ice in PBS using a glass tissue homogenizer then centrifuged at 35 000 x g for 30 minutes in a Beckman JA20 rotor (4degreesC). Membranes were washed once more with PBS at 4degreesC then resuspended in 1 ml PBS/100 mm dish. Protein content was determined using a Lowry assay (Sigma. Diagnostics, St. Louis, MO). Membranes were initially prepared and Bmax and Kd values determined in the presence and absence of a cocktail of protease inhibitors (Complete Protease Inhibitor Cocktail, Roche Diagnostics, Mannheim Germany). No change in Bmax was observed as a result of omitting the protease inhibitor (Bmax (+ protease inhibitor)= 3.1 +/- 0.11 pmoles/mg protein vs Bmax (- protease inhibitor) = 3.2 +/- 0.13 pmoles/mg protein.) hence all assays were performed in the absence of the cocktail. Binding assays were performed in PBS.
###end p 51
###begin p 52
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 116 117 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 163 164 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 207 208 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 290 291 283 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 411 414 404 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 418 419 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">n</sup>
###xml 426 427 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">n</sup>
###xml 431 432 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">n</sup>
###xml 461 464 454 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
For Kd determinations, 100 mul of homogenate was incubated at 37degreesC for 1 hour with varying concentrations of [3H]granisetron (NEN, MA). Specific binding of [3H]granisetron was determined as the bound [3H]granisetron not displaced by a saturating concentration of a competing ligand. Kd values were determined by fitting the binding data to the following equation using Graphpad PRISM (San Diego CA): B = Bmax [L]n / ([L]n + Kn), where B is bound ligand, Bmax is the maximum binding at equilibrium L is the free ligand concentration and n is the Hill coefficient.
###end p 52
###begin p 53
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 127 128 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 223 225 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 351 353 340 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 398 399 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 497 498 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 549 551 534 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 600 601 581 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 627 629 608 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
Ki determinations, 100 mul of homogenate was incubated at 37degreesC for 2 hours with varying concentrations of inhibitor and [3H]granisetron (NEN, MA). Binding was terminated by rapid filtration onto a GF/B filters. The IC50 values were calculated by fitting the data to the following equation using Graphpad PRISM (San Diego CA): theta = 1/ (1+(L/IC50)), where theta is the fractional amount of [3H]granisetron bound in the presence of inhibitor at concentration L as compared to the amount of [3H]granisetron bound in the absence of inhibitor. IC50 is the concentration at which theta = 0.5. The Ki is calculated from the IC50 value using the Cheng-Prusoff equation.
###end p 53
###begin title 54
Electrophysiological Recordings
###end title 54
###begin p 55
###xml 117 118 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 292 293 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1024 1026 1020 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 1032 1033 1028 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">n</sup>
###xml 1097 1099 1093 1095 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
Transfected cells were transferred to a recording chamber containing extracellular solution (140 mM NaCl, 1.7 mM MgCl2, 5 mM KCl, 1.8 mM CaCl2, 25 mM HEPES pH 7.4). Patch electrodes of resistance 2.5-3.0 MOmega were filled with filtered intracellular solution containing 145 mM KCl, 2 mM MgCl2, 1 mM EGTA, 25 mM HEPES (pH 7.4). Cells were clamped in whole cell configuration at a holding potential of -60 mV. A continuous extracellular solution flow (0.8 ml/min) was maintained throughout the recording procedure. 5-HT was dissolved in extracellular solution and delivered to cells using a rapid perfusion system (Warner Instruments, Hamden, CT) at a rate matching the extracellular solution flow rate. The drug perfusions lasted for a period varying from 4 to 8 seconds. Currents elicited by agonist application were measured using an Axopatch 200 B amplifier (Foster City, CA). The data were plotted and analyzed by non-linear curve fitting (Graphpad PRISM, San Diego CA) according to the following equation: I = 1/(1 +(EC50/ [C])n), where is the normalized current at 5-HT concentration [C], EC50 is the concentration of 5-HT needed to obtain half maximal activation and n is the apparent Hill coefficient.
###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
This work was supported by The University of Louisiana at Monroe, College of Pharmacy and grants from the Southeast Affiliate of the American Heart Association. We would also like to gratefully acknowledge Dr. Karen Kirschbaum at The University of Louisiana at Monroe, Monroe, LA for providing us with the lerisetron used in these studies.
###end p 57
###begin article-title 58
Primary structure and functional expression of the 5-HT3R, serotonin gated ion channel.
###end article-title 58
###begin article-title 59
Towards a structural basis for the function of nicotinic acetylcholine recetors and their cousins
###end article-title 59
###begin article-title 60
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family.
###end article-title 60
###begin article-title 61
Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors.
###end article-title 61
###begin article-title 62
###xml 71 77 <span type="species:ncbi:10090">murine</span>
Cloning and functional expression of an apparent splice variant of the murine 5-HT3 receptor A subunit.
###end article-title 62
###begin article-title 63
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AS</sub>
###xml 39 44 <span type="species:ncbi:9606">human</span>
Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit.
###end article-title 63
###begin article-title 64
A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX.
###end article-title 64
###begin article-title 65
###xml 62 65 <span type="species:ncbi:10116">rat</span>
Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium.
###end article-title 65
###begin article-title 66
###xml 72 74 72 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A</sub>
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3B</sub>
The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-HT3B receptor subunit.
###end article-title 66
###begin article-title 67
Functional architecture of the nicotinic acetylcholine receptor: A prototype of ligand gated ion channels.
###end article-title 67
###begin article-title 68
Nicotinic receptors at the amino acid level.
###end article-title 68
###begin article-title 69
Structure of the agonist-binding sites of the torpedo nicotinic acetylcholine receptor: affinity-labelling and mutational analysis identify gamma Tyr-111/delta Arg-113 as antagonist affinity determinants.
###end article-title 69
###begin article-title 70
Molecular dissection of subunit interfaces in the acetylcholine receptor: identification of residues that determine curare selectivity.
###end article-title 70
###begin article-title 71
Molecular dissection of subunit interfaces in the acetylcholine receptor: identification of determinants of alpha-conotoxin M1 selectivity.
###end article-title 71
###begin article-title 72
Identification of equivalent residues in the, gamma, delta delta and epsilon subunits of the nicotinic receptor that contribute to alpha-bungarotoxin binding.
###end article-title 72
###begin article-title 73
Identification of two amino acid residues in the epsilon subunit that promote mammalian muscle acetylcholine receptor assembly in COS cells.
###end article-title 73
###begin article-title 74
Intersubunit contacts governing assembly of the mammalian nicotinic acetylcholine receptor.
###end article-title 74
###begin article-title 75
###xml 33 38 <span type="species:ncbi:9606">human</span>
Decreased agonist sensitivity of human GABA(A) receptors by an amino acid variant, isoleucine to valine, in the alpha1 subunit.
###end article-title 75
###begin article-title 76
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Expression of recombinant homo-oligomeric 5-hydroxytryptamine3 receptors provides new insights into their maturation and structure.
###end article-title 76
###begin article-title 77
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Structural features of the ligand-binding domain of the serotonin 5HT3R.
###end article-title 77
###begin article-title 78
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Analysis of the ligand binding site of the 5-HT3R using site directed mutagenesis: Importance of glutamate 106.
###end article-title 78
###begin article-title 79
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT3 receptors in N1E-115 neuroblastoma cells.
###end article-title 79
###begin article-title 80
A glia-derived acetylcholine-binding protein that modulates synaptic transmission.
###end article-title 80
###begin article-title 81
Crystal structure of an Ach-binding protein reveals the ligand-binding domain of nicotinic receptors.
###end article-title 81
###begin article-title 82
###xml 81 83 81 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A</sub>
Importance of phenylalanine 107 in agonist recognition by the 5-hydroxytryptamine3A receptor.
###end article-title 82
###begin article-title 83
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The role of tryptophan residues in the 5-hydroxytryptamine3 receptor ligand binding domain.
###end article-title 83
###begin article-title 84
###xml 85 87 85 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A</sub>
Molecular determinanats of (+)tubocurarine binding at recombinant 5-hydroxytryptamine3A receptor subunits.
###end article-title 84
###begin article-title 85
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
New 2-Piperazinylbenzimidazole derivatives as 5HT3 antagonists. Synthesis and pharmacological Evaluation.
###end article-title 85
###begin article-title 86
###xml 78 79 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 27 32 <span type="species:ncbi:9606">human</span>
A single amino acid of the human gamma-aminobutyric acid type A receptor gamma2 subunit determines benzodiazepine efficacy.
###end article-title 86
###begin article-title 87
Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit.
###end article-title 87

